SCHEMBL30765883

SCHEMBL30765883

CO[C@@H]1CO[C@H]2[C@@H]1OC[C@H]2Oc1ccc(N)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 6/20 0.39
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 4/20 0.38
CYP3A4 P08684 2/20 0.38
APP P05067 2/20 0.37
TSHR P16473 2/20 0.36
ERBB2 P04626 7/20 0.35
EPHA2 P29317 7/20 0.35
KDR P35968 7/20 0.35
EPHB4 P54760 7/20 0.35
FLT1 P17948 3/20 0.35
BCHE P06276 1/20 0.34
NR4A1 P22736 1/20 0.33
EGFR P00533 1/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
HPGD P15428 1/20 0.33
NFKB1 P19838 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28477039 0.91 TDP1 (0.39) TDP1MAPK1ALDH1A1CYP3A4APP
SCHEMBL31558424 0.83 APP (0.34) APPERBB2EPHA2KDREPHB4
SCHEMBL18589288 0.80 BCHE (0.48) TDP1ALDH1A1TSHRERBB2EPHA2
SCHEMBL18582506 0.80 BCHE (0.48) TDP1ALDH1A1TSHRERBB2EPHA2
SCHEMBL30765561 0.80 CA2 (0.44) ERBB2EPHA2KDREPHB4FLT1
SCHEMBL31558434 0.77 ALDH1A1 (0.40) MAPK1ALDH1A1CYP3A4APPBCHE
SCHEMBL14713886 0.75 LMNA (0.43) TDP1MAPK1ALDH1A1BCHEMAPT
SCHEMBL14713885 0.75 LMNA (0.43) TDP1MAPK1ALDH1A1BCHEMAPT
SCHEMBL22604496 0.75 CA1 (0.43)
SCHEMBL18589290 0.75 BCHE (0.51) BCHEMAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed